Feng Li

Title: Feng Li: Advancing Research on Direct Thrombin Inhibitors.

Introduction

Feng Li is an inventor associated with Baylor College of Medicine in Houston, Texas. His patent work focuses on compounds that inhibit thrombin and their potential use in addressing blood clotting and bleeding disorders.

Latest Patents

Li is associated with 1 patent, titled “Direct Thrombin Inhibitors and Methods of Use Thereof.” The patent describes novel direct thrombin inhibitors and methods for using them as anticoagulants. The compounds and compositions are presented as potential tools for treating or preventing thromboembolism and bleeding or clotting disorders, as well as for inhibiting thrombin in cells.

Career Highlights

Li’s listed patent reflects research into therapeutic approaches that target thrombin, an important component of blood coagulation. His work connects the development of inhibitor compounds with methods for their potential medical use.

Collaborations

Li’s listed coworker is Surendra Dawadi. Their association reflects collaborative work connected with the patent on direct thrombin inhibitors.

Conclusion

Feng Li’s patent work at Baylor College of Medicine centers on direct thrombin inhibitors and their potential applications in managing thromboembolism and bleeding or clotting disorders.